Fobeni Healthcom, a joint venture between Shanghai Fosun Pharmaceutical and Marubeni, has unveiled an advanced food-grade (glucagon-like peptide-1) GLP-1 product.
The new GLP-1 product, dubbed WASLIM Bifidobacterium Shortum Compound Drink, was developed under a strategic collaboration between Fobeni and TCI.
TCI is an original design manufacturer (ODM) of dietary supplements and cosmetics with over 40 years of expertise, and its products are available in 65 countries.
The new product incorporates TCI’s GLP-1 formula, a natural blend of plant extracts, probiotics, and prebiotics designed to deliver powerful weight management results.
GLP-1 is an incretin hormone primarily, secreted by L-cells in response to nutrient intake in the intestine, to enhance insulin secretion and inhibit glucagon release.
It signals satiety to the brain, suppresses appetite through central nervous system mechanisms, and delays gastric emptying, thereby reducing hunger sensations.
TCI leverages its unique Bio-Resource Data Mining methodology, an automated, cloud-based, AI-driven system to autonomously identify natural active compounds.
The company has developed its GLP-1 formula using in-vitro validations and human trials.
In the human trials, the new formula showed efficacy in promoting GLP-1 secretion and regulating blood glucose levels.
In-vitro studies further validated its effectiveness in stimulating natural GLP-1 production from intestinal L-cells, which is a crucial step in controlling appetite and promoting fat loss.
TCI also conducted a study of its new GLP-1 formula, in which the 560 participants lost an average of 4.9kg, with a total weight loss of 2,732kg across the group.
TCI’s GLP-1 formula offers clinical benefits, including enhanced GLP-1 secretion, stabilised postprandial blood glucose, and proven weight management efficacy.
Fobeni in its statement said: “The GLP-1 formula showed notable effects in reducing blood glucose and total cholesterol levels. In some subjects, average fasting blood glucose decreased by 1.42%, while total cholesterol dropped by 4.2%.
“Moreover, beneficial HDL (high-density lipoprotein) levels increased by 2.93%, and LDL (low-density lipoprotein) levels decreased by 2.71%, significantly lowering the risk of cardiovascular diseases linked to high cholesterol.
“These results suggest that the GLP-1 formula may have considerable benefits for weight loss and overall health, providing participants with motivation to continue their journey toward a healthier lifestyle.”
